Biotechnology companies are producing remarkable therapies at an unprecedented pace. In the past year, two new gene therapies have come to market for patients suffering from sickle cell disease. Rapid advancements are being made in how we treat cancers, such as CAR-T. From innovative materials for prosthetic joint replacements to advances in organ transplantation, the future of medicine has never been brighter. Yet all of this progress hinges on the availability of effective antimicrobials - one field of medicine where innovation and investment has lagged. This session will bring together a diverse range of perspectives and experiences to analyze the cross-cutting threat of AMR while also exploring policy solutions that could incentivize private investors to return to antimicrobial R&D and replenish the pipeline.